Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Basit Öğe Kaydı
dc.contributor.authorDemirci, Umut
dc.contributor.authorTufan, Gulnihal
dc.contributor.authorAktas, Bilge
dc.contributor.authorBalakan, Ozan
dc.contributor.authorAlacacioglu, Ahmet
dc.contributor.authorDane, Faysal
dc.contributor.authorEngin, Huseyin
dc.date.accessioned2024-04-24T16:01:54Z
dc.date.available2024-04-24T16:01:54Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy. A total of 115 patients with grade IV glial tumor (n = 93) and grade III glial tumor (n = 22) were retrospectively evaluated at 14 centers in Turkey. Primary objectives of the study were to evaluate the efficacy and toxicity of the bevacizumab and irinotecan as salvage treatment based on response to therapy, progression-free survival (PFS), 6 months of PFS, overall survival (OS), and 6 months of OS (OS6). Bevacizumab and irinotecan were performed as second line (79.1 %) and third line treatment (20.9 %). Median chemotherapy cycle was 6 (range 1-37), and median follow-up was 6 months (range 1-36 months). Objective response rate was 39.1 %. Six-month PFS and OS6 were 46.3 % and 67.5 %, respectively. Median PFS was 6 months (95 % CI 2.5-9.5) and 6 months (95 % CI 4.9-7.1) in the grade III and IV groups, respectively (p = 0.773). Median OS was 9 months (95 % CI 7.1-10.9) and 8 months (95 % CI 6.6-9.4) in the grade III and IV groups, respectively (p = 0.450). Serious toxicities were observed in 7.8 % of patients. Treatment-related toxic death was observed in 3 patients. There was no treatment related to central nervous system hemorrhage or other serious hemorrhages. Present study results were consistent with previous studies. In addition, we detected similar outcomes in grade III and IV glial tumors.en_US
dc.identifier.doi10.1007/s00432-013-1390-8
dc.identifier.endpage835en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue5en_US
dc.identifier.pmid23400732
dc.identifier.scopus2-s2.0-84876290291
dc.identifier.scopusqualityQ3
dc.identifier.startpage829en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-013-1390-8
dc.identifier.urihttps://hdl.handle.net/11468/14471
dc.identifier.volume139en_US
dc.identifier.wosWOS:000317649100012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBevacizumaben_US
dc.subjectIrinotecanen_US
dc.subjectRecurrent Diseaseen_US
dc.subjectMalignant Gliomaen_US
dc.titleBevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)en_US
dc.titleBevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu